Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms

Blood

Volumn 100, Issue 3, 2002, Pages 743-754

  Ariëns, Robert A S ^a,b,c,d   Lai, Thung Shenq ^a,b,c   Weisel, John W ^a,b,c   Greenberg, Charles S ^a,b,c   Grant, Peter J ^a,b,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; CALCIUM ION; COLLAGEN; FIBRIN; FIBRINOGEN; FIBRONECTIN; THROMBIN;

BINDING SITE; BLOOD CLOTTING; CATALYSIS; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FIBRIN CLOT; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS; STROKE; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS; X RAY CRYSTALLOGRAPHY;

EID: 0036682920     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.3.743     Document Type: Review

References (164)

1. Human factor XIII from plasma and platelets: Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin
2. Relationships of the catalytic properties of human plasma and platelet transglutaminases (activated blood coagulation factor XIII) to their subunit structures
3. A study of human coagulation factor XIII A-subunit by electrospray ionization mass spectrometry
4. Factor XIII in human plasma and platelets
5. Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain
6. Monocytes of patients congenitally deficient in plasma factor XIII lack factor XIII subunit a antigen and transglutaminase activity
7. Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease
8. Biosynthesis of factor XIII A and B subunits
9. Coagulation factor XIII A and B subunits in bone marrow and liver transplantation
10. Three-dimensional structure of a transglutaminase: Human blood coagulation factor XIII
11. Two nonproline cis peptide bonds may be important for factor XIII function
12. Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII
13. Regulation of formation of factor XIIla by its fibrin substrates
14. The subunit structures of human plasma and platelet factor XIII (fibrin-stabilizing factor)
15. Die molekulare Struktur der fibrinstabilisierenden Faktoren des Menschen
16. Amino acid sequence of the b subunit of human factor XIII, a protein composed of ten repetitive segments
17. Nucleotide sequence of the gene for the b subunit of human factor XIII
18. Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin
19. Thrombin-independent activation of platelet factor XIII by endogenous platelet acid protease
20. Platelet factor XIII is activated by calpain
21. Interactions of factor XIII with fibrin as substrate and cofactor
22. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII
23. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen
24. Cleavage of blood coagulation factor XIII and fibrinogen by thrombin during in vitro clotting
25. Factor XIIla formation promoted by complexing of alpha-thrombin, fibrin, and plasma factor XIII
26. Alpha-thrombin-catalyzed activation of human platelet factor XIII: Relationship between proteolysis and factor XIIIa activity
27. Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen
28. Kinetic studies with transglutaminases: The human blood enzymes activated coagulation factor 13 and the guinea pig hair follicle enzyme
29. Regulation of plasma factor XIII binding to fibrin in vitro
30. A model for fibrinogen: Domains and sequence
31. The structure and function of the αC domains of fibrinogen
32. Fibrin-recombinant human factor XIII A-subunit association
33. Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa): Calcium ion regulatory aspects
34. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains
35. Structure of the human gamma-fibrinogen gene: Alternate mRNA splicing near the 3′ end of the gene produces gamma A and gamma B forms of gamma-fibrinogen
36. Carboxyterminal amino acid sequence of a human fibrinogen gamma-chain variant (gamma')
37. Identification and characterization of the thrombin binding sites on fibrin
38. Characterization of the reciprocal binding sites on human α-thrombin and factor XIII A-chain
39. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation
40. Fibrinase I: Purification of substrate and enzyme
41. Lysine as amine donor in fibrin crosslinking
42. The identification of isopeptide crosslinks in insoluble fibrin
43. Analysis of the catalytic activity of human factor XIIIa by site-directed mutagenesis
44. Role of calcium ion in the generation of factor XIII activity
45. Calcium-dependent unmasking of active center cysteine during activation of fibdn stabilizing factor
46. Structure and function studies of factor XIIIa by x-ray crystallography
47. Inhibition of clotting factor XIII activity by nitric oxide
48. Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras
49. Substrate requirements for transglutaminases: Influence of the amino acid residue preceding the amine donor lysine in a native protein
50. GlyPro-Arg-Pro modifies the glutamine residues in the alpha- and gamma-chains of fibrinogen: Inhibition of transglutaminase cross-linking
51. A double-headed Gly-Pro-Arg-Pro ligand mimics the functions of the E domain of fibrin for promoting the end-to-end crosslinking of gamma chains by factor XIIIa
52. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin
53. Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments
54. Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (Bitis arietans) acting at cross-linked sites of the gamma-chain: Sequence of carboxy-terminal cyanogen bromide gamma-chain fragments
55. Cross-linked fibrinogen dimers demonstrate a feature of the molecular packing in fibrin fibers
56. Chromatography and electron microscopy of cross-linked fibrin polymers: A new model describing the cross-linking at the DD-trans contact of the fibrin molecules
57. Orientation of the carboxy-terminal regions of fibrin gamma chain dimers determined from the crosslinked products formed in mixtures of fibrin, fragment D, and factor XIIIa
58. Amino acid sequence studies on the α chain of human fibrinogen: Exact location of cross-linking acceptor sites
59. Localization of the alpha-chain cross-link acceptor sites of human fibrin
60. Factor XIIIa-catalyzed cross-linking of recombinant αC fragments of human fibrinogen
61. Factor XIII: Structure, activation, and interactions with fibrinogen and fibrin
62. Identification of the α chain lysine donor sites involved in factor XIIIa fibrin cross-linking
63. Fibrin crosslinks and lysis rates
64. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis
65. Electron microscopy of fine fibrin clots and fine and coarse fibrin films: Observations of fibers in cross-section and in deformed states
66. Plasmic degradation of crosslinked fibrin: Characterization of new macromolecular soluble complexes and a model of their structure
67. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
68. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor
69. Acceleration of fibrinolysis by the N-terminal peptide of alpha 2-plasmin inhibitor
70. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII: Its effect on fibrinolysis
71. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis
72. Cross-linking of collagen and fibronectin by factor XIIIa: Localization of participating glutaminyl residues to a tryptic fragment of fibronectin
73. Factor XIII catalyzed formation of fibrinogen-fibronectin oligomers: A thiol enhanced process
74. Factor XIII-induced crosslinking in solutions of fibrinogen and fibronectin
75. Inhibitory effect of fibronectin on the fibrin formation
76. Fibronectin and fibrin gel structure
77. Importance of plasma fibronectin in determining PFP and PRP clot mechanical properties
78. Modification of shear modulus and creep compliance of fibrin clots by fibronectin
79. Factor XIIIa-mediated cross-linking of fibronectin in fibroblast cell layers: Cross-linking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments
80. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa
81. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa
82. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets
83. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilization
84. Platelet-associated factor XIII as a marker of platelet activation in patients with peripheral vascular disease
85. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface
86. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues
87. Organization of the gene for human erythrocyte membrane protein 4.2: Structural similarities with the gene for the a subunit of factor XIII
88. Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24-p25
89. Localization of the gene for coagulation factor XIII a-chain to chromosome 6 and identification of sites of synthesis
90. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor
91. Localization of the coagulation factor XIII B subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment length polymorphism at the locus
92. Internal homologies of the Ba fragment from human complement component Factor B, a class III MHC antigen
93. Amino acid sequence studies of human C4b-binding protein: N-terminal sequence analysis and alignment of the fragments produced by limited proteolysis with chymotrypsin and the peptides produced by cyanogen bromide treatment
94. A complement receptor locus: Genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32
95. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1
96. Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP): Evidence for inclusion in the multigene family of complement-regulatory proteins
97. Coagulation factor XIII B subunit is encoded by a gene linked to the regulator of complement activation (RCA) gene cluster in man
98. Linkage analyses of human peptidase C (PEPC), human factor H (HF), and coagulation factor XIIIB (F13B)
99. Deficiency in the A-subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on transcript levels
100. Molecular basis of inherited factor XIII deficiency: Identification of multiple mutations provides insights into protein function
101. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene
102. Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with high or low factor XIII specific activity
103. Molecular basis for the subtypic differences of the "a" subunit of coagulation factor XIII with description of the genesis of the subtypes
104. Type I factor XIII deficiency is caused by a genetic defect of its B subunit: Insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain
105. Arg260-Cys mutation in severe factor XIII deficiency: Conformational change of the A subunit is predicted by molecular modelling and mechanics
106. Transcriptional regulation of cell type-specific expression of the TATA-less A subunit gene for human coagulation factor XIII
107. Tetranucleotide repeat polymorphism at the human coagulation factor XIII A subunit gene (F13A1)
108. Association of a common polymorphism in the factor XIII gene with myocardial infarction
109. Prevalence of FXIII V34L in populations with different cardiovascular risk
110. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism
111. A common coding polymorphism in the FXIII A-subunit gene (FXIII Val34Leu) affects cross-linking activity
112. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
113. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A
114. Val34Leu polymorphism of plasma factor XIII: Biochemistry and epidemiology in familial thrombophilia
115. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation
116. Interaction of the factor XIII activation peptide with α-thrombin: Crystal structure of its enzyme-substrate analog complex
117. Thrombin hydrolysis of V29F and V34L mutants of factor XIII (28-41) reveals roles of the P9 and P4 positions in factor XIII activation
118. Fibrin assembly: Lateral aggregation and the role of the two pairs of fibrinopeptides
119. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots
120. Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerisation mechanism
121. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography
122. Genetic polymorphism of the B subunit of human coagulation factor XIII
123. Identification of a human specific Alu insertion in the factor XIIIB gene
124. A novel polymorphism in the factor XIII B subunit (His95Arg) relates to the dissociation of the A2B2 tetramer
125. Interaction between insulin resistance and factor XIII Val34Leu in patients with coronary artery disease
126. Clustering of haemostatic risk factor with FXIIIVal34Leu in patients with myocardial infarction
127. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males
128. Factor XIII Val34Leu and the risk of myocardial infarction
129. A common mutation in the gene for coagulation factor XIII-A (Val34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases
130. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women
131. Genetic polymorphisms and coronary artery disease in the South of France
132. Factor XIIIA Val34Leu polymorphism does not predict risk of coronary artery disease: The atherosclerosis risk in communities (ARIC) study
133. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism
134. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angioplasty
135. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease
136. Association of a common polymorphism in the factor XIII gene with venous thrombosis
137. Factor XIII Val34Leu is a genetic factor involved in the aetiology of venous thrombosis
138. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: Common mutations of blood coagulation factors and deep vein thrombosis in Austria
139. Factor XIII Val34Leu polymorphism and risk of deep vein thrombosis
140. Factor XIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers
141. α-fibrinogen Thr312Ala polymorphism and venous thromboembolism
142. The association of the α-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation
143. Factor XIII Val 34 Leu: A novel association with primary intracerebral hemorrhage
144. Polymorphisms of clotting factor modify the risk for primary intracranial hemorrhage
145. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction
146. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women
147. Role of factor XIII Val34Leu polymorphism in retinal artery occlusion
148. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism
149. Inhibition of factor XIIIa in a canine model of coronary thrombosis: Effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator
150. Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases: Evidence for transglutaminase-catalyzed cross-linking to fibrin
151. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen)
152. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAl-2)
153. Covalent crosslinking of von Willebrand factor to fibrin
154. Binding and covalent cross-linking of purified von Willebrand factor to native monomeric collagen
155. Vitronectin is a substrate for transglutaminases
156. Sequence location of a putative transglutaminase cross-linking site in human vitronectin
157. Incorporation of thrombospondin into fibrin clots
158. Factor V is a substrate for the transamidase factor XIIIa
159. Covalent crosslinking of human coagulation factor V by activated factor XIII from guinea pig megakaryocytes and human plasma
160. Cross-linking of actin and fibrin by fibrin-stabilizing factor
161. Factor XIIIa-catalyzed cross-linking of platelet and muscle actin: Regulation by nucleotides
162. Fibrinoligase-catalyzed cross-linking of myosin from platelet and skeletal muscle
163. Platelet vinculin: A substrate of activated factor XIII
164. Disulfide-linked and transglutaminase-catalyzed protein assemblies in platelets